<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04042233</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00022651</org_study_id>
    <nct_id>NCT04042233</nct_id>
  </id_info>
  <brief_title>Intraosseous Vancomycin in Primary Total Hip Arthroplasty - Designing a Protocol</brief_title>
  <official_title>Intraosseous Vancomycin in Primary Total Hip Arthroplasty - Designing a Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Methodist Hospital System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Methodist Hospital System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate a novel vancomycin intraosseous administration
      protocol vs a standard IV vancomycin administration protocol for primary total hip
      arthroplasty patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are randomized to one of two groups.

      GROUP A - Will receive IV antibiotics (cefepime &amp; vancomycin) are started in pre-op
      approximately 1 hour prior to incision vancomycin dose weight-based at approximately 15mg/kg,
      generally 1000-1750mg in 500 milliliters (mL) normal saline (NS).

      GROUP B - Will have IV cefepime started in pre-op within 1 hour of incision. Intraosseous
      (IO) administration of vancomycin (500mg in 250 milliliters NS) will be administered in the
      OR after sterile prep and draping has occurred. Injection will take place into the greater
      trochanter (within a pre-specified region).

      Both Groups will be monitored during surgery and immediately post-operatively for adverse
      injection reactions (i.e. Red Man Syndrome). Both groups will otherwise follow identical
      post-operative protocols (including post-operative antibiotic administration).

      TISSUE SAMPLES Five (5) tissue samples will be taken from each patient, 2 soft tissue samples
      and 3 bone samples will be taken throughout the course of the procedure.

      One blood sample will be taken in both groups intraoperatively at the time of initiation of
      closure.

      These samples will immediately be sent to a lab for analysis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 31, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systemic Vancomycin level</measure>
    <time_frame>1 year</time_frame>
    <description>vancomycin blood level at time of initiation of closure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tissue vancomycin level</measure>
    <time_frame>1 year</time_frame>
    <description>at start and end of case.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Femur vancomycin level</measure>
    <time_frame>1 year</time_frame>
    <description>at start and end of case.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acetabulum vancomycin level</measure>
    <time_frame>1 year</time_frame>
    <description>at start and end of case.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-Day Complications</measure>
    <time_frame>From the administration of antibiotics perioperatively to 30 days post op.</time_frame>
    <description>Complications 30 days post surgery i.e. infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-Day Complications</measure>
    <time_frame>From the administration of antibiotics perioperatively to 90 days post op.</time_frame>
    <description>Complications 90 days post surgery i.e. infection</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Prosthetic Joint Infection</condition>
  <condition>Vancomycin</condition>
  <condition>Joint Diseases</condition>
  <arm_group>
    <arm_group_label>IV administration of vancomycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard IV vancomycin administration protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IO Vancomycin 500mg in 250 mL NS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental Intraosseous administration protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental Intraosseous vancomycin 500mg in 250 mL NS</intervention_name>
    <description>500mg of Vancomycin in 250 mL of normal saline will be injected into a pre-specified region of the greater trochanter during primary total hip arthroplasty.</description>
    <arm_group_label>IO Vancomycin 500mg in 250 mL NS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard IV administration of vancomycin</intervention_name>
    <description>IV antibiotics (cefepime &amp; vancomycin) are started in pre-op approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg, generally 1000-1750mg in 500 mL NS).</description>
    <arm_group_label>IV administration of vancomycin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is undergoing a primary total hip arthroplasty

          -  Patient gives informed consent to participate in the study.

          -  Age Range &gt;18

        Exclusion Criteria:

          -  Previous surgery on the hip (including hip scopes)

          -  BMI above 35

          -  Contraindication to receiving vancomycin or cefepime (allergy, medical issue, etc)

          -  Inability to locate the greater trochanter or administer the IO infusion

          -  Refusal to participate

          -  Diabetes

          -  Immunocompromised or immunosuppressed patients (HIV, Hep C, End stage renal disease,
             dialysis, transplant, chemo/radiation treatment in last 6 months, medications).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen J Incavo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Methodist Hospital System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas C Sullivan, B.S.</last_name>
    <phone>346-238-1603</phone>
    <email>tsullivan@houstonmethodist.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Dong, B.S.</last_name>
    <phone>713-363-7390</phone>
    <email>ddong@houstonmethodist.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Sullivan, BS</last_name>
    </contact>
    <investigator>
      <last_name>Terry Clyburn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesca Taraballi, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 30, 2019</study_first_submitted>
  <study_first_submitted_qc>July 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2019</study_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Methodist Hospital System</investigator_affiliation>
    <investigator_full_name>Terry Clyburn</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>total hip arthroplasty</keyword>
  <keyword>vancomycin</keyword>
  <keyword>intraosseous vancomycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Joint Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

